Advances in Lipid-Based Co-delivery Systems for Cancer and Inflammatory Diseases.

Combination therapy targeting multiple therapeutic targets is a favorable strategy to achieve better therapeutic outcomes in cancer and inflammatory diseases. Co-delivery is a subfield of drug delivery that aims to achieve combined delivery of diverse therapeutic cargoes within the same delivery system, thereby ensuring delivery to the same site and providing an opportunity to tailor the release kinetics as desired. Amongst the wide range of materials being investigated in the design of co-delivery systems, lipids have stood out on account of their low toxicity, biocompatibility, and ease of formulation scale-up. This review highlights the advances of the last decade in lipid-based co-delivery systems focusing on the co-delivery of drug-drug, drug-nucleic acid, nucleic acid-nucleic acid, and protein therapeutic based combinations for targeted therapy in cancer and inflammatory diseases. This article is protected by copyright. All rights reserved.